Palifermin
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 65 (15) , 2139-2146
Abstract
▴ Palifermin, a recombinant human keratinocyte growth factor (KGF), mimics the actions of endogenous KGF and has shown efficacy in the management of myelotoxic therapy-induced oral mucositis in cancer patients. ▴ In a randomised, double-blind trial in patients with haemtaological malignancies receiving conditioning radiochemotherapy before undergoing autologous stem cell transplant, intravenous palifermin 60 μg/kg/day (two 3-day cycles, administered before myelotoxic therapy and after transplant) significantly reduced the median duration (primary endpoint) [3 vs 9 days] and incidence (63% vs 98%) of WHO grade 3 or 4 oral mucositis, compared with placebo. ▴ Patient-reported outcomes also showed significant improvement with palifermin treatment, which was associated with significant reductions in healthcare resource utilisation, compared with placebo. ▴ The drug was generally well tolerated, with skin/ oral toxicities, pain/arthralgias and dysaesthesia being the most common palifermin-related adverse reactions.Keywords
This publication has 12 references indexed in Scilit:
- Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): Experimental studies in miceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositisCancer, 2004
- Perspectives on cancer therapy-induced mucosal injuryCancer, 2004
- Keratinocyte growth factor: effects on keratinocytes and mechanisms of actionEuropean Journal of Cell Biology, 2004
- The burdens of cancer therapyCancer, 2003
- Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal ProtectantJournal of Clinical Oncology, 2003
- Amelioration of acute oral mucositis by Keratinocyte growth factor: fractionated irradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell TransplantationJournal of Clinical Oncology, 2001
- Effects of Keratinocyte Growth Factor on the Proliferation and Radiation Survival of Human Squamous Cell Carcinoma Cell Lines In Vitro and In VivoInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998